EnVena
Financiado
Automatic vein wall disruption, triggering the body’s natural cellular healing r...
Automatic vein wall disruption, triggering the body’s natural cellular healing response to close targeted veins curing Venous Leg Ulcers
Chronic venous disease is one of the most common diseases in the developed world, affecting up to 60% of adults over the age of 50. Chronic venous disease is the leading cause of Venous Leg Ulcers which are chronic open sores, us...
Chronic venous disease is one of the most common diseases in the developed world, affecting up to 60% of adults over the age of 50. Chronic venous disease is the leading cause of Venous Leg Ulcers which are chronic open sores, usually on the inside of the leg that will not heal without specialist treatment.
The total costs associated with managing venous disease patients across Europe and the US is €33.4 billion per year, representing 2.5% of total healthcare expenditure.
Most patients are treated with ineffective compression bandaging which does not treat the underlying cause and has an unacceptably high recurrence rate. These bandages are also sent to landfill with a high environmental impact
EnVena is the world’s first device to mimic the body’s natural healing response to deliver an effective treatment to venous leg ulcer patients.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2022-09-15
Fecha Fin: 2024-09-30
Fecha Fin: 2024-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-ACCELERATOROPEN-01:
EIC Accelerator Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
INVERA MEDICAL LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
